All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
NICE recommendation of acalabrutinib for patients with treatment-naïve CLL
By Sumayya Khan
Bookmark this article
On March 18, 2021, it was announced that the National Institute for Health and Care Excellence (NICE) in England recommend the use of acalabrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia (CLL).
This recommendation is for patients with a TP53 mutation or 17p deletion, or for patients without these mutations but where fludarabine plus cyclophosphamide and rituximab, or bendamustine plus rituximab is unsuitable. As acalabrutinib is administered as a twice daily tablet, the recommendation is of particular benefit during the current COIVD-19 pandemic because patients can self-administer from home.
This recommendation comes after the European approval previously discussed on the Lymphoma Hub.
- Chemotherapy-free treatment option to be offered to patients with England’s most common leukaemia. https://www.nice.org.uk/news/article/chemotherapy-free-treatment-option-to-be-offered-to-patients-with-england-s-most-common-leukaemia. Published Mar 18, 2021. Accessed Mar 19, 2021.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youRelated articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox